• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcus faecalis.与六种化合物相比，HMR 3647对235株粪肠球菌的活性。
Antimicrob Agents Chemother. 1999 Jan;43(1):166-8. doi: 10.1128/AAC.43.1.166.
2
In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.两种酮内酯类药物HMR 3647和HMR 3004对革兰氏阳性菌的体外活性
Antimicrob Agents Chemother. 1999 Apr;43(4):930-6. doi: 10.1128/AAC.43.4.930.
3
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine).百日咳博德特氏菌和副百日咳博德特氏菌对两种酮内酯（HMR 3004和HMR 3647）、四种大环内酯类抗生素（阿奇霉素、克拉霉素、红霉素A和罗红霉素）以及两种安莎霉素（利福平和利福喷汀）的体外敏感性。
Antimicrob Agents Chemother. 1998 Apr;42(4):965-6. doi: 10.1128/AAC.42.4.965.
4
Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans.将HMR 3004（RU 64004）和HMR 3647（RU 66647）与红霉素、阿奇霉素、克拉霉素、罗红霉素以及其他八种抗菌药物对从人类皮肤和软组织感染中分离出的不常见需氧和厌氧人及动物咬伤病原体的活性进行比较。
Antimicrob Agents Chemother. 1998 May;42(5):1127-32. doi: 10.1128/AAC.42.5.1127.
5
Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole.与四种大环内酯类、五种β-内酰胺类、克林霉素和甲硝唑相比，酮内酯RU 64004的抗厌氧活性。
Antimicrob Agents Chemother. 1997 May;41(5):1037-41. doi: 10.1128/AAC.41.5.1037.
6
Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains.新型酮内酯类抗菌剂（HMR 3004和HMR 3647）对流感嗜血杆菌和卡他莫拉菌菌株的抗菌活性比较及杀菌曲线研究。
Diagn Microbiol Infect Dis. 1998 Jun;31(2):349-53. doi: 10.1016/s0732-8893(98)00022-4.
7
Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004).酮内酯类药物HMR 3647（RU 66647）和HMR 3004（RU 64004）的抗厌氧活性比较
Antimicrob Agents Chemother. 1997 Sep;41(9):2019-22. doi: 10.1128/AAC.41.9.2019.
8
Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.将青霉素敏感及耐药、红霉素敏感及耐药的肺炎球菌对新型酮内酯类药物HMR 3647（RU 66647）的敏感性与对其他17种药物的敏感性进行比较。
Antimicrob Agents Chemother. 1998 Mar;42(3):624-30. doi: 10.1128/AAC.42.3.624.
9
Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.通过时间杀菌法比较泰利霉素（HMR 3647）与其他八种药物对厌氧菌的活性。
Antimicrob Agents Chemother. 1999 Aug;43(8):2027-31. doi: 10.1128/AAC.43.8.2027.
10
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.新型酮内酯类抗菌剂HMR 3647的体外活性
J Antimicrob Chemother. 1998 Dec;42(6):703-9. doi: 10.1093/jac/42.6.703.

引用本文的文献

1
The ketolides: a critical review.酮内酯类药物：综述
Drugs. 2002;62(12):1771-804. doi: 10.2165/00003495-200262120-00006.
2
In vitro activities of the new ketolide HMR 3647 (telithromycin) in comparison with those of eight other antibiotics against viridans group Streptococci isolated from blood of neutropenic patients with cancer.新型酮内酯类药物HMR 3647（泰利霉素）与其他八种抗生素对从癌症中性粒细胞减少患者血液中分离出的草绿色链球菌的体外活性比较。
Antimicrob Agents Chemother. 2001 Feb;45(2):624-6. doi: 10.1128/AAC.45.2.624-626.2001.

本文引用的文献

1
In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.新型酮内酯类抗生素RU 64004对革兰氏阳性菌的体外活性
Antimicrob Agents Chemother. 1997 May;41(5):1196-202. doi: 10.1128/AAC.41.5.1196.
2
Antimicrobial activity of RU-66647, a new ketolide.新型酮内酯RU-66647的抗菌活性
Diagn Microbiol Infect Dis. 1997 Jan-Feb;27(1-2):7-12. doi: 10.1016/s0732-8893(96)00181-2.
3
Increasing problems in the therapy of enterococcal infections.肠球菌感染治疗中日益增多的问题。
Eur J Clin Microbiol Infect Dis. 1993 Jun;12(6):409-12. doi: 10.1007/BF01967433.
4
Genetics and mechanisms of glycopeptide resistance in enterococci.肠球菌中糖肽类耐药的遗传学及机制
Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71. doi: 10.1128/AAC.37.8.1563.
5
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.采用时间杀菌法对青霉素G、RP 59500、红霉素、司帕沙星、环丙沙星和万古霉素的抗肺炎球菌活性进行比较研究。
Antimicrob Agents Chemother. 1994 Sep;38(9):2065-72. doi: 10.1128/AAC.38.9.2065.
6
High-level resistance to aminoglycosides: comparison of community and nosocomial fecal isolates of enterococci.
Clin Infect Dis. 1995 Apr;20(4):1048-51. doi: 10.1093/clinids/20.4.1048.
7
Vancomycin resistance in the enterococcus. Relevance in pediatrics.
Pediatr Clin North Am. 1995 Jun;42(3):601-18. doi: 10.1016/s0031-3955(16)38981-7.
8
Antibiotic resistance in enterococci.
J Antimicrob Chemother. 1989 Nov;24(5):631-5. doi: 10.1093/jac/24.5.631.
9
Ampicillin-resistant enterococcal species in an acute-care hospital.一家急症护理医院中对氨苄西林耐药的肠球菌属菌种
Antimicrob Agents Chemother. 1990 Sep;34(9):1821-3. doi: 10.1128/AAC.34.9.1821.
10
Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward.产β-内酰胺酶、耐氨基糖苷类的粪肠球菌在婴幼儿外科病房的患者和医护人员中迅速传播。
N Engl J Med. 1990 Dec 27;323(26):1814-8. doi: 10.1056/NEJM199012273232606.

与六种化合物相比，HMR 3647对235株粪肠球菌的活性。

Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcus faecalis.

作者信息

Hoellman D B, Lin G, Jacobs M R, Appelbaum P C

机构信息

Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033, USA.

出版信息

Antimicrob Agents Chemother. 1999 Jan;43(1):166-8. doi: 10.1128/AAC.43.1.166.

DOI:10.1128/AAC.43.1.166
PMID:9869585
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC89040/
Abstract

Agar dilution was used to test the activities of HMR 3647, erythromycin A, azithromycin, clarithromycin, roxithromycin, clindamycin, and quinupristin-dalfopristin against 235 strains of Enterococcus faecalis. HMR 3647 was the most active compound (MICs at which 50 and 90% of the isolates are inhibited [MIC50 and MIC90, respectively] of 0.06 and 4.0 microg/ml, respectively). The MIC50 and MIC90 (with the MIC50 given first and the MIC90 given second; both in micrograms per milliliter) for other compounds were as follows: 4.0 and >32.0 for erythromycin A, 16.0 and >32.0 for azithromycin, 2.0 and >32 for clarithromycin, 32.0 and >32.0 for roxithromycin, 32.0 and >32.0 for clindamycin, and 8.0 and 16.0 for quinupristin-dalfopristin. All compounds were only bacteriostatic.

摘要

采用琼脂稀释法检测HMR 3647、红霉素A、阿奇霉素、克拉霉素、罗红霉素、克林霉素和奎奴普丁-达福普汀对235株粪肠球菌的活性。HMR 3647是活性最强的化合物（分别抑制50%和90%分离株的最低抑菌浓度[分别为MIC50和MIC90]分别为0.06和4.0微克/毫升）。其他化合物的MIC50和MIC90（先给出MIC50，后给出MIC90；单位均为微克/毫升）如下：红霉素A为4.0和>32.0，阿奇霉素为16.0和>32.0，克拉霉素为2.0和>32，罗红霉素为32.0和>32.0，克林霉素为32.0和>32.0，奎奴普丁-达福普汀为8.0和16.0。所有化合物均仅具有抑菌作用。